tHEORetically Speaking
AMNOG was the end of paradise for pharmaceutical companies, correct Prof. Hammerschmidt?
What have been the main changes after 10 years of AMNOG for pharmaceutical companies? What have been the biggest successes within these years? For orphan drug the benefit evaluation process was eased in order to keep incentives high. Have price expectations been up met - by both sides? After 10 [...]
Podcast Q&A: Informing Market Access Earlier in Clinical Development: Prospective RWE Research to Characterize Real World Patient Populations
This podcast segment from Self Care Catalysts' June 29, 2022 webinar features the Q&A with Renee Willmon, MSc, Senior Director, Evidence and Outcomes, Global Market Access. If you do not see the embedded media player above, access the podcast episode here. There is often a conflict between [...]
Podcast Q&A: Understanding Health Care Decision Maker Preferences for Optimized Engagement
This podcast segment from ICON's June 23, 2022 webinar features the Q&A with panel participants as they discussed best practices and preferences for information sharing with health care decision makers. If you do not see the embedded media player above, access the podcast episode here. In this [...]
What is the secret of the cost-efficient healthcare system in Israel, Mirel Stelian?
Israel spends only 7.6% of the GDP on healthcare – significantly less than most other Western OECD countries. At the same time Israel has a higher life expectancy and lower infant mortality. So, better results for less money?! How does Israel do this? Dr. Stefan Walzer and Mirel Stelian are [...]
Real-World Data for Mental Health – Understanding Outcomes and Unlocking Pathways to More Precise Treatments
OM1 was founded by a team dedicated to the belief that participating in value-based healthcare requires a much more complete view of patient outcomes than what has been available until now. With that principle in mind, OM1 has built the largest electronically-connected mental health specialty network in the United States [...]
Dutch payers are pragmatic, especially when discussing medical devices, isn’t it, Ron de Graff?
The market access process in the Netherlands can be very special, especially for medical devices. Besides standard reimbursement processes with evidence-based medicine assessments, there are also more pragmatic pathways available. How do these work and what needs to be considered before moving into the Dutch health care market? Listen to the [...]
Podcast Q&A: FDA Guidance Documents: Shaping the Future of RWD Curation and RWE Innovation
This podcast segment features the Q&A from IQVIA's May 25, 2022 webinar hosted IQVIA experts Raina Olexa, Senior Principal Scientist Regulatory Science and Strategy, and Mui Van Zandt, VP and GM Real World Data and Technology, as they answer questions on embracing FDA’s guidance on the use of real world [...]
The Belgium reimbursement pathway for digital health applications is similarly easy as in Germany, correct Katrien de Groote?
Belgium has created a similar fast-track process as in Germany even though that some differences exist. Anyway, core question with new processes is always how the rules are being interpreted and applied. So, how important are clinical studies and when are those required? What are the price levels and negotiations [...]
Unlocking the Value of Real-World Data to Provide Real-World Care
For this tHEORetically speaking video interview, we spoke with Mary Tran, MS, from Syapse for a deep dive into the strengths, weaknesses, and challenges of real-world data (RWD). Mary also explains some effective multi-source RWD strategies to transform patient data into patient experience. Read a transcript of the interview below! [...]
Boston Strategic Partners Supplier Spotlight
Supplier Spotlight® highlights the unique skills and services offered by organizations who are part of our CONNECTED COMMUNITY™. We recently spoke with experts from Boston Strategic Partners, Inc. (BSP), for insights into their global advisory firm that offers five different types of services exclusively to the life sciences industry. Read [...]
Is European market access really so difficult? Tell us the truth about being successful in Europe, Esther Nzenza!
Europe is one continent, with one Union (plus the UK)… Health policy is still the responsibility of each individual country and hence there are still (at least) as many reimbursement pathways as countries. Planning for business success in health care is hence difficult? Not necessarily according to Dr. Stefan Walzer [...]
HealthLumen Supplier Spotlight
HealthLumen's mission is to improve global health outcomes by creating data-driven insights for decision making. We are specialists in quantifying the burden of chronic diseases into the future.
Trends and challenges in the Value, Evidence, and Access landscape: an interview with David Sykes, Head of VEA, Fishawack Health
For this installment of tHEORetically speaking, David Sykes sat down with HealthEconomics.com to provide an overview of Fishawack Health (FH) and its core competencies, what sets FH apart from other solution providers for life science commercialization, and digital applications offered by the company. David Sykes also describes current [...]
What can Europeans learn from Canada for the upcoming EU joint HTA, Gabriel Tremblay?
EU joint HTA will become reality in the next few years as communicated recently by the European Commission. However, applicability and implementation questions are still open such as timing, inclusion into national regulations and HTA processes in the EU member states. In Canada a similar process, including a single joint [...]
Differentiate Your Product From the Competition: Give Healthcare Decision Makers the Information They Need
In this competitive pharmaceutical market access landscape, payers are preparing budgets and financial forecasts well ahead of product launches, meaning they require product information earlier and earlier in the pre-approval stage. Patti Peeples, PhD of HealthEconomics.com sits down with Xcenda’s National Director of Business Development, Tom Liberta and Head [...]